Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Arterial stiffness is a hallmark of vascular ageing and results in increased blood flow
pulsatility to the periphery, damaging end-organs such as the heart, kidneys and brain …

Aims Sodium/glucose transporter 2 (SGLT2 or SLC5A2) inhibitors lower blood glucose and
are also approved treatments for heart failure independent of raised glucose. Various …

Neflamapimod, a selective inhibitor of the alpha isoform of p38 mitogen-activated protein
kinase (MAPKα), was investigated for its potential to inhibit lipopolysaccharide (LPS) …

Background and aims The effect of dapagliflozin (DAPA) on the prognosis of patients with
acute myocardial infarction (AMI) is unclear. The present study was conducted to evaluate …

Introduction The role of dapagliflozin on erectile dysfunction (ED), a condition widely
affecting patients with type 2 diabetes mellitus (T2DM), has not yet been studied. Aim The …

Dapagliflozin, a sodium–glucose co-transporter 2 (SGLT2) inhibitor, is an antidiabetic
medication that reduces blood glucose. Although it is well known that dapagliflozin has …

Purpose The aim of this study was to investigate the effects and mechanisms of SGLT2
inhibitor empagliflozin on diabetic coronary function. Methods A rat diabetic model was …

Introduction In this study, a meta-analysis was conducted to investigate the therapeutic effect
of Dapagliflozin (DAPA) on animals suffering from myocardial ischemia reperfusion …

Introduction Sodium dependent glucose transporter 2 (SGLT2 or SLC5A2) inhibitors
effectively lower blood glucose and are also approved treatments for heart failure …